

## Effect of Cadmium-Mobilizing Dithiocarbamates on Essential Trace Metal Metabolism in Rats

B. Kargačin,<sup>1</sup> M. Blanuša,<sup>1</sup> R. Arežina,<sup>1</sup> K. Kostial,<sup>1</sup> P. K. Singh,<sup>2</sup> and M. Jones<sup>2</sup>

<sup>1</sup>Institute for Medical Research and Occupational Health, University of Zagreb, M. Pijade 158, 41000 Zagreb, Yugoslavia and <sup>2</sup>Department of Chemistry and Center in Molecular Toxicology, Vanderbilt University, Nashville, Tennessee 37235, USA

Dithiocarbamate analogs have been shown as the most effective chelating agents in mobilizing cadmium from rodents (Jones et al., 1988; Gale et al., 1989). High efficacy of these agents has been shown in mice and rats, both in cases of early and late administration after cadmium introduction into the body (Jones et al., 1988; Gale et al., 1989). Beside their high efficacy, in the case of their late application, these agents have advantages over other chelants used for cadmium elimination since they have much lower toxicity (Kojima et al., 1987).

One of the possible explanations for the pathogenesis of toxic chelate effects is based on the interaction between chelating agent and endogenous essential metals. The stability of the calcium chelates is lower by several orders of magnitude than the stability of the chelates formed with endogenous essential trace metals and the toxicity of such chelating agents may be therefore due to the mobilization or binding in situ of certain metals and a consequent impairment of metal-controlled or -activated systems. Thus it has been shown that CaEDTA when given at a normal therapeutic dosage to humans, leads to an increased urinary excretion of Fe, Mn, Cu and particularly Zn (Teisinger and Fišerova-Bergerova, 1958; Truhaut et al., 1966). Repeated administration of toxic doses of CaDTPA resulted in an extensive reduction of the Mn content in liver and small intestine (Nadolny, 1971). The Zn content in skeleton, pancreas, small intestine and testes, show only a slight transient decrease (Auth, 1973) under such conditions. Apparently, the depleted Zn stores are replenished rapidly by Zn absorbed from the

Send reprint requests to K. Kostial at the above address.

intestine. Slobodien et al. (1973) observed that when CaDTPA was applied over an extended period of time in humans, each CaDTPA dose resulted in a urinary Zn excretion 20-30 times higher than the pretreatment levels. This indicates that the depletion of Zn stores is transient. 2,3-dimercaptopropane-1-sulfonate (DMPS) and D-penicillamine (PA) significantly increased copper excretion and decreased its concentration in the kidney (Planas-Bohne, 1979).

The purpose of the present study was to evaluate the effect of three chelating agents N-benzyl-N-dithiocarboxy-D-glucamine (BDCG), N-methyl-N-dithiocarboxy-D-glucamine (MDCG) and sodium N-(4-methoxybenzyl)-D-glucamine dithiocarbamate monohydrate (MeOBDCG) which were previously found very effective in reducing cadmium retention and enhancing its elimination from the body on concentrations of some essential elements in the liver and kidney in rats and on their urinary exerction.

## MATERIALS AND METHODS

The experiment was performed on 6-week-old albino female rats (about 140 g body weight) from the Institute's breeding farm. They received standard rat diet and tap water ad libitum and were placed in individual metabolic cages for collection of urine. They were divided into four groups according to the chelating agent administration. The first group served as a control and received during 10 days 0.9% saline solution intraperitoneally. The second group received N-benzyl-N-dithiocarboxy-D-glucamine (BDCG), the third group N-methyl-N-dithiocarboxy-D-glucamine (MDCG) and the fourth sodium N-(4-methoxybenzyl)-D-glucamine dithiocarbamate monohydrate (MeOBDCG). Chelating agents were administered intraperitoneally daily for 10 days at a dose of 0.5 mmol/kg body weight/day. 24 hr after the last treatment rats were anaesthetized with ether and exanguinated. Excess moisture from the liver and kidneys was removed by filter paper and the wet weight determined. The right kidney and about 2 g of liver tissue from various parts were wet digested with nitric acid (DS-40, Tecator, Sweden) for trace element analysis by flame atomic absorption spectrophotometry (Pye Unicam SP 9). During the first two and last two days of the experiment, the urine was collected for trace element analysis with the exception of the group which received MDCG. Urine was evaporated and dry ashed at 450 °C. The ash was dissolved in 2 per cent nitric acid adjusted to 10 ml and iron, zinc, copper and calcium were measured by flame atomic absorption spectrophotometry. For statistical treatment of data Student, s t-test was used (significance level P<0.01).

Table 1. Concentration of iron, zinc and copper in the liver and kidney (µg/g wet tissue)

			Fe	Zn	Cu
LIVER	20 <sup>c</sup> 20 10 10	c <sup>a</sup> E <sub>1</sub> E <sub>2</sub> E <sub>3</sub>	176.4± 7.9 <sup>b</sup> 189.7± 6.7 178.0± 8.0 202.5±14.6	40.0±0.9 40.4±1.1 42.1±0.9 36.9±1.1	8.1±0.8 8.9±0.7 6.1±0.4 10.4±1.2
KIDNEY	20 10 10 10	C E <sub>1</sub> E <sub>2</sub> E <sub>3</sub>	52.7 <u>+</u> 1.6 56.0 <u>+</u> 4.4 62.0 <u>+</u> 3.2 53.7 <u>+</u> 1.6	30.2±0.6 30.2±1.1 29.9±0.6 31.1±0.7	12.6±0.7 9.1±0.7 9.6±0.4 <sup>e</sup> 15.3±1.2

<sup>&</sup>lt;sup>a</sup>C - control group received i.p. 0.9% saline

Chelating agents BDCG (E $_1$ ), MDCG (E $_2$ ), MeOBDCG (E $_3$ ) were administered intraperitoneally at a dose of 0.5 mmol/kg body weight during 10 days.

Table 2. Excretion of iron, zinc, copper and calcium in urine (µg/48 hr)

		Fe	Zn	Cu	Ca
CONTROL	II	18.4 <u>+</u> 2.1 <sup>b</sup> 22.8 <u>+</u> 5.2	36.1 <u>+</u> 3.0 49.2 <u>+</u> 3.7	11.4 <u>+</u> 1.3 19.7 <u>+</u> 2.5	6.3 <u>+</u> 1.3 9.6 <u>+</u> 0.6
E <sub>1</sub> -BDCG <sup>a</sup>	I II	16.8 <u>+</u> 2.5 14.0 <u>+</u> 2.2	35.7 <u>+</u> 2.5 41.3 <u>+</u> 2.7	10.0 <u>+</u> 1.3 11.3 <u>+</u> 1.1 <sup>c</sup>	10.0 <u>+</u> 1.0 11.3 <u>+</u> 0.9
E <sub>3</sub> -MeOBDCG	II	18.0 <u>+</u> 3.0 29.4 <u>+</u> 7.0	38.6 <u>-</u> 4.2 47.6 <u>+</u> 3.1	21.9 <u>+</u> 3.9 26.3 <u>+</u> 5.4	9.3 <u>+</u> 1.4 11.2 <u>+</u> 0.5

<sup>&</sup>lt;sup>a</sup>Chelating agents BDCG ( $E_1$ ) and MeOBDCG ( $E_3$ ) were administered i.p. at a dose of 0.5 mmol/kg body weight during 10 days.

Urine was collected during first (I) and last (II) 2 days (48 hr) of the experiment  $\,$ 

<sup>&</sup>lt;sup>b</sup>Arithmetic mean <u>+</u> SEM

<sup>&</sup>lt;sup>C</sup>Number of animals in the group

<sup>&</sup>lt;sup>d</sup>P<0.01 compared to controls

eP<0.001 compared to controls

<sup>&</sup>lt;sup>b</sup>Arithmetic mean <u>+</u> SEM of 10 animals in each group.

<sup>&</sup>lt;sup>C</sup>P<0.01 compared to controls

## RESULTS AND DISCUSSION

During the experimental period of 10 days the weight gain was similar in all three groups (about 13 g - 8%). The concentrations of analyzed trace elements in the liver and the kidney were in most groups, similar to the control values (Table 1). Only the concentration of Cu in the kidney after BDCG and MDCG treatment was lower than in the control group. The administration of BDCG or MeOBDCG did not increase the excretion of trace elements in urine (BDCG even decreased Cu elimination) (Table 2). The results obtained indicate that in our experimental conditions chelation therapy did not increase essential element excretion from the body. This is different from the results obtained previously with other chelating agents. With the exception of modest reductions in the copper levels of the kidneys for BDCG and MDCG, the iron, zinc and copper levels of the liver and the kidneys were not significantly different from those of the controls. The urinary excretion of iron, zinc, copper and calcium were also not significantly higher from those of the controls. It should be mentioned that changes in trace element content after CaEDTA or CaDTPA treatment were usually observed with single administration of high doses (2-4 mmol/kg body weight; Nadonly, 1971; Auth, 1973). The dose used in our experiment was lower (0.5 mmol/kg b. w.) but given during 10 days. The results obtained are interesting since until now this aspect of dithiocarbamate treatment was not investigated. High efficacy and low toxicity of these dithiocarbamate analogs indicate their possible applicability in cases of chronic cadmium intoxication.

Acknowledgments. We thank Mrs D. Breški and M. Ciganović for technical assistance and Mrs M. Horvat for preparing the manuscript.

## REFERENCES

- Auth U (1973) Metabolismus und Toxizität therapeutischer Chelatbildner. XIII Mitteilung: Einfuss von Ca-DTPA auf die Zn-Konzentration der Organe. Strahlentherapie 146:490-497
- Gale GR, Atkins LA, Smith AB, Singh PK, Jones MM (1989) N,N-Disubstituted dithiocarbamates as cadmium antagonists: N-(4-methoxybenzyl)-N-dithiocarboxy-D-glucamine. Toxicol Lett 48:105-108
- Jones SG, Singh PK, Jones MM (1988) Use of the Topliss scheme for the design of more effective chelating agents for cadmium decorporation. Chem Res Toxicol: 234-237
- Kojima S, Kiyozumi M, Honda T, Kuminaka K, Oda Y, Senba

- Y (1987) Effect of N-benzyl-D-glucamine dithiocarbamate on distribution and excretion of cadmium in rats. Toxicology 45:93-102
- Nadolny W (1971) Metabolismus und Toxizität Therapeuscher Chelatbildner. 10. Mitteilung: Die Ausscheidung von endogenem Mangan. Strahlentherapie 141: 100-105
- Planas-Bohne F (1979) Influence of several chelating agents on the excretion and organ concentration of copper in the rat. Toxicol Appl Pharmacol 50:337-345
- Slobodien MJ, Brodsky A, Ke CH, Horm I (1973) Removal of zinc from humans by DTPA chelation therapy. Health Phys 24:327-330
- Teisinger J, Fišerova-Bergerova V (1958) Uber den Einfluss des zur Therapie der Bleivergiftung angewendeten Calciumdinatrium-salzes der Äthylendiamintetraessigsaure auf den Eisen und Kupferspiegel im Blut und Urin. Arch Gewerbepath Gewerbehyg 16:478-489
- Truhaut R, Boudene Cl, Lutz M (1966) Recherches dans la série des complexones. Ann Biol Clin 24:419-439 Received July 9, 1990; accepted December 27, 1990.